{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-22-012165","form_type":"8-K","ticker":"COLL","cik":"0001267565","company_name":"COLLEGIUM PHARMACEUTICAL, INC","filed_at":"2022-08-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.195818+00:00","generated_at":"2026-06-24T03:46:10.488619+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Collegium Q2 revenue $123.5M record, raises FY Adj EBITDA guidance to $245-255M","bullets":["Q2 net product revenue $123.5M (record), up from $82.9M YoY.","GAAP net loss $5.2M ($0.15 loss per share) vs $72.8M income in prior year (included tax benefit).","Adjusted EBITDA $71.2M, up from $40.1M YoY; full-year Adj EBITDA guidance raised to $245-255M.","BDSI integration complete; on track to exceed targeted run-rate synergies of at least $75M.","Opioid lawsuits resolved via master settlement agreement covering 27 pending cases."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-22-012165","json":"https://secwatch.observer/filing/0001558370-22-012165.json","markdown":"https://secwatch.observer/filing/0001558370-22-012165.md","text":"https://secwatch.observer/filing/0001558370-22-012165.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1267565/000155837022012165/0001558370-22-012165-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1267565/000155837022012165/coll-20220804x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T03:46:10.488619+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}